Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | CCKAR | P32238 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11988282 | 1.00 | PTGS2 (0.46) | PTGS2PTGS1CCKARCYP1A2CYP3A4 | |
| SCHEMBL2150807 | 0.88 | CCKAR (0.46) | PTGS2PTGS1CCKAR | |
| SCHEMBL11988293 | 0.88 | CCKAR (0.46) | PTGS2PTGS1CCKAR | |
| SCHEMBL11988277 | 0.88 | CCKAR (0.46) | PTGS2PTGS1CCKAR | |
| SCHEMBL2150519 | 0.88 | CCKAR (0.46) | PTGS2PTGS1CCKAR | |
| SCHEMBL2150619 | 0.88 | CCKAR (0.46) | PTGS2PTGS1CCKAR | |
| SCHEMBL11988284 | 0.86 | CCKAR (0.46) | PTGS2PTGS1CCKAR | |
| SCHEMBL11988415 | 0.85 | PTGS2 (0.41) | PTGS2PTGS1CYP3A4CYP2C9TSHR | |
| SCHEMBL11928277 | 0.84 | PTGS2 (0.48) | PTGS2PTGS1CCKARCYP1A2CYP3A4 | |
| SCHEMBL11928275 | 0.84 | PTGS2 (0.48) | PTGS2PTGS1CCKARCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565184-B1 | THERAPEUTIC AGENT AND PREVENTATIVE AGENT FOR ALZHEIMER'S DISEASE | TORAY INDUSTRIES (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-2554541-B1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA | TORAY INDUSTRIES (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-8957094-B2 | Therapeutic agent or prophylactic agent for fibromyalgia | TORAY INDUSTRIES, INC. (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2341047-B1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2562160-B1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR URINE COLLECTION DISORDER | TORAY INDUSTRIES (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-8642625-B2 | Therapeutic agent or preventive agent for urine collection disorder | TORAY INDUSTRIES, INC. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-8598212-B2 | Therapeutic agent and preventative agent for alzheimer's disease | TORAY INDUSTRIES, INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130190503-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA | TORAY INDUSTRIES, INC. (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-2565184-A1 | THERAPEUTIC AGENT AND PREVENTATIVE AGENT FOR ALZHEIMER'S DISEASE | Toray Industries, Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2562160-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR URINE COLLECTION DISORDER | Toray Industries, Inc. (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20130041157-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR URINE COLLECTION DISORDER | TORAY INDUSTRIES, INC. (JP) | 2013-02-14 | — | — | US | disclosed |
| US-20130041158-A1 | THERAPEUTIC AGENT AND PREVENTATIVE AGENT FOR ALZHEIMER'S DISEASE | TORAY INDUSTRIES, INC. (JP) | 2013-02-14 | — | — | US | disclosed |
| EP-2554541-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA | Toray Industries, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-8349874-B2 | Cyclohexane derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120270906-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2012-10-25 | — | — | US | disclosed |
| US-8247569-B2 | Cyclohexane derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20110201650-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2341047-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2011-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190503-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA | FAAH, GAP43, FAP | PTGS2 198/4885PTGS1 82/4885CCKAR 2441/4885 |
| US-20130041157-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR URINE COLLECTION DISORDER | UROD, SORD, IDUA | PTGS2 1550/4885PTGS1 1149/4885CCKAR 2204/4885 |
| US-20120270906-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | CNR2, CNR1, TRPV1 | PTGS2 238/4885PTGS1 259/4885CCKAR 31/4885 |
| US-20130041158-A1 | THERAPEUTIC AGENT AND PREVENTATIVE AGENT FOR ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | PTGS2 739/4885PTGS1 476/4885CCKAR 1142/4885 |
| US-20110201650-A1 | CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | CNR2, TRPV1, OPRL1 | PTGS2 93/4885PTGS1 89/4885CCKAR 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.